Evidence map›Paper›PMID 27857126›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Repeated 7-Day Treatment with the 5-HT

Matthew L Banks, S Stevens Negus

Abstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Evaluation of the 5-HTPharmacological reports : PR · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Medications Development for Treatment of Opioid Use Disorder.Cold Spring Harbor perspectives in medicine · 2021
    Review
  14. Article
  15. Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0003-4949-5246
S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.

Funding

Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7M
NIDA NIH HHS R01 DA026946
6 · The paper itself

Abstract

Cocaine use disorder is a global public health problem for which there are no Food and Drug Administration-approved pharmacotherapies. Emerging preclinical evidence has implicated both serotonin (5-HT) 2C and 2A receptors as potential mechanisms for mediating serotonergic attenuation of cocaine abuse-related neurochemical and behavioral effects. Therefore, the present study aim was to determine whether repeated 7-day treatment with the 5-HT

Indexed as

AnimalsBenzazepinesChoice BehaviorCocaineCocaine-Related DisordersDose-Response Relationship, DrugFeeding BehaviorMacaca mulattaMalePiperidinesReinforcement ScheduleSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsUreaBenzazepinesCocainelorcaserinpimavanserinPiperidinesSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsUrea

Identifiers

PMID27857126
PMCPMC5506793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.